Zynex, Inc. Reaffirms Earnings Guidance for the Fourth Quarter and Full Year 2022
January 17, 2023 at 09:15 am EST
Share
Zynex, Inc. reaffirmed earnings guidance for the fourth quarter and full year 2022. For the fourth quarter, the company confirming its previous estimates for fourth quarter revenue between $48.0-$51.0 million.
For the full year 2022, the company revenue estimate now ranges between $157.4-$160.4 million.
Zynex, Inc. develops, manufactures, markets and sells medical devices used for pain management and rehabilitation, as well as non-invasive fluid, sepsis and laser-based pulse oximetry monitoring systems for use in hospitals. The Companyâs devices are intended for pain management to reduce reliance on medications and provide rehabilitation and increased mobility through the utilization of non-invasive muscle stimulation, electromyography technology, interferential current, neuromuscular electrical stimulation and transcutaneous electrical nerve stimulation. The Companyâs products include Zynex Medical Products, which includes NexWave, NeuroMove, InWave, E-Wave and M-Wave; Private Labeled Supplies, which includes Electrodes and Batteries; Distributed Complementary, which includes Comfortrac/Saunders, JetStream/Pain Management Technologies, LSO Back Braces and Bracing, and Zynex Monitoring Solutions Products, which includes CM-1500, CM-1600, NiCO CO-Oximeter and HemeOx tHb Oximeter.
ZYNEX, INC. 
